艾蒿花粉变应原免疫治疗变应性鼻炎的疗效和安全性评估

摘要

目的：回顾性评价艾蒿变应原制剂治疗艾蒿花粉过敏性鼻炎的疗效和安全性。方法回顾10年里接受艾蒿花粉变应原免疫治疗（SIT）的艾蒿花粉过敏性鼻炎患者，比较SIT治疗3年后过敏性鼻炎临床症状的严重程度，症状持续时间，治疗药物，皮肤点刺、艾蒿特异性IgE（specific IgE,sIgE）、总体自评和不良反应。结果196例SIT治疗三年后，皮肤点刺试验的反应性较治疗前明显降低，血清特异性IgE水平显著降低。鼻炎症状总评分、药物积分差异均有统计学意义（P＜0.001,Z=-7.524；P＜0.001,Z=-6.012），89%总体自评为病情改善。9例患者发生全身不良反应。其中Ⅱ类7例次(泛发的荨麻疹)Ⅲ类2例次（泛发的荨麻疹合并血管性水肿）。所有患者总体自评均为明显改善，无致死性不良反应。结论使用艾蒿花粉变应原制剂可有效、安全地治疗艾蒿花粉过敏性鼻炎。%Objective To evaluate the efficacy and safety of allergen specific immunotherapy (SIT) for Mugwort pollen-allergic rhinitis (AR) by using Mugwort pollen extract.Methods AR patient who was prescribes SIT only by Mugwort pollen extract during the past 10 years.were reviewed in this study.Symptom score,duration of symptom in pollen season,medication score and self-assessment of AR were medication score and self-assessment were also assessed the patients.Results Symptom score of AR,(P<0.001,Z=-7.524; P<0.001,Z=-6.012);and medication score of AR,P<0.01 was statistic significantly improved for pre-and after SIT; Self-assessment was improved among 89%oatuebts.Systemic reactions were recoded among 9 patients,which belong to type Ⅱ7 and type Ⅲ2 respectively. Patients′self-assessment was also improved.Conclusion SIT with Mugwort pollen extract is an effective and safety treatment for Mugwort pollen-AR patients.